Applied Materials, Inc. (NASDAQ: AMAT) received an upgrade to Overweight from Tom O’Malley of Barclays on January 15, 2026, signaling potential for substantial growth as the firm sets a price target ...
On January 15, 2026, Applied Materials, Inc. (NASDAQ: AMAT) received a notable boost with an upgrade to “Overweight” from Tom O’Malley at Barclays, solidifying investor interest in this semiconductor ...
Wells Fargo analyst Joe Quatrochi upgraded Analog Devices, Inc. (ADI) to an “Overweight” rating while adjusting the firm’s price target for the stock to $340, up from a previous consensus of $301.25.
On January 15, 2026, Barclays analyst Tom O’Malley upgraded Applied Materials, Inc. (AMAT) to an Overweight rating. This new assessment comes with a price target increase to $360, suggesting ...
Albertsons Companies, Inc. (NYSE: ACI) has recently been downgraded to an Underweight rating by Simeon Gutman of Morgan Stanley, a significant shift that reflects growing investor caution toward the ...
Essex Property Trust, Inc. (ESS) received a “Market Perform” rating from John Kim at BMO Capital on January 9, 2026, a ...
Kazuya Nishimura is an analyst from Daiwa Capital specializing in the Financial Services sector. They are beginning to establish their track record, with 2 stock rating s so far. Their current stats ...
Arbe Robotics Ltd. (ARBE) Jumps 15% in Pre-market: Strong CES Showcasing Enhances Investor Sentiment
Summary • Arbe Robotics Ltd. (ARBE) rises 15% in pre-market trading, reaching $1.38 after CES 2026 showcasing. • The company ...
Summary • CeriBell, Inc. (CBLL) jumps 23% in pre-market trading following FDA Breakthrough Device Designation for a stroke ...
Equity Residential (NYSE: EQR) has recently been assigned a “Market Perform” rating by analyst John Kim from BMO Capital, reflecting a cautious outlook for investors amid mixed performance indicators.
MoonLake Immunotherapeutics (MLTX) is garnering attention in the investment community following a recent upgrade to a Buy rating from BTIG analyst Julian Harrison. This bullish outlook comes with a ...
HealthEquity, Inc. (HQY) has recently been downgraded to a “Sell” rating by David Roman of Goldman Sachs, with a price target slashed to $89 from earlier estimates. This change comes at a time when ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results